Poly(ADP-ribose) in the skin and in melanomas

Histology and Histopathology

Volumn 27, Issue 5, 2012, Pages 651-659

  Géhl, Zsuzsanna ^a,b   Bai, Péter ^a,c   Bodnár, Edina ^a   Emri, Gabriella ^a   Remenyik, Éva ^a   Németh, János ^b   Gergely, Pál ^a,c   Virág, László ^a,c   Szabó, Éva ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Melanoma; Poly(ADP ribose); Poly(ADP ribose) polymerase; Skin

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ADIPOCYTE; ADULT; AGED; ARTICLE; CHILD; CYTOLOGY; DRUG ANTAGONISM; ENDOTHELIUM CELL; FEMALE; HAIR FOLLICLE; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN; SKIN TUMOR; UVEA TUMOR;

ADIPOCYTES; ADULT; AGED; AGED, 80 AND OVER; CHILD; ENDOTHELIAL CELLS; FEMALE; HAIR FOLLICLE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MALE; MELANOMA; MIDDLE AGED; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 84859303857     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Ahmed I. (1997). Malignant melanoma: prognostic indicators. Mayo Clin. Proc. 72, 356-361.
2. Ame J.C., Spenlehauer C. and de Murcia G. (2004). The PARP superfamily. Bioessays 26, 882-893.
3. Bai P., Hegedus C., Szabo E., Gyure L., Bakondi E., Brunyanszki A., Gergely S., Szabo C. and Virag L. (2009). Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity. J. Invest. Dermatol. 129, 234-238.
4. Bakondi E., Bai P., Szabo E., Hunyadi J., Gergely P., Szabo C. and Virag L. (2002). Detection of poly(ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate. J. Histochem. Cytochem. 50, 91-98.
5. Bakondi E., Gonczi M., Szabo E., Bai P., Pacher P., Gergely P., Kovacs L., Hunyadi J., Szabo C., Csernoch L. and Virag L. (2003). Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes. J. Invest. Dermatol. 121, 88-95.
6. Bakondi E., Bai P., Erdelyi K., Szabo C., Gergely P. and Virag L. (2004). Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism. Exp. Dermatol. 13, 170-178.
7. Bakos L., Wagner M., Bakos R.M., Leite C.S., Sperhacke C.L., Dzekaniak K.S. and Gleisner A.L. (2002). Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil. Int. J. Dermatol. 41, 557-562.
8. Blasi M.A., Maresca V., Roccella M., Roccella F., Sansolini T., Grammatico P., Balestrazzi E. and Picardo M. (1999). Antioxidant pattern in uveal melanocytes and melanoma cell cultures. Invest. Ophthalmol. Vis. Sci. 40, 3012-3016.
9. Cals-Grierson M.M. and Ormerod A.D. (2004). Nitric oxide function in the skin. Nitric Oxide 10, 179-193.
10. Chalmers A.J. (2009). The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull. 89, 23-40.
11. Dao H. Jr and Kazin R.A. (2007) Gender differences in skin: a review of the literature. Gend. Med. 4, 308-328.
12. De Murcia G. and Menissier de Murcia J. (1994). Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends. Biochem. Sci. 19, 172-176.
13. Erdelyi K., Bakondi E., Gergely P., Szabo C. and Virag L. (2005). Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell. Mol. Life Sci. 62, 751-759.
14. Erdelyi K., Bai P., Kovacs I., Szabo E., Mocsar G., Kakuk A., Szabo C., Gergely P. and Virag L. (2009). Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. FASEB J. 23, 3553-3563.
15. Farkas B., Magyarlaki M., Csete B., Nemeth J., Rabloczky G., Bernath S., Literati N.P. and Sumegi B. (2002). Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor. Biochem. Pharmacol. 63, 921-932.
16. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H. and de Bono J.S. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134.
17. Garbe C., Buttner P., Bertz J., Burg G., d'Hoedt B., Drepper H., Guggenmoos-Holzmann I., Lechner W., Lippold A., Orfanos C.E., Peters A., Rassner G., Stadler R. and Stroebel W. (1995). Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75, 2484-2491.
18. Guerry D.T. and Schuchter L.M. (1992). Disseminated melanoma--is there a new standard therapy? N. Engl. J. Med. 327, 560-561.
19. Hagberg H., Wilson M.A., Matsushita H., Zhu C., Lange M., Gustavsson M., Poitras M.F., Dawson T.M., Dawson V.L., Northington F. and Johnston M.V. (2004) PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J. Neurochem. 90, 1068-75.
20. Hassa P.O. and Hottiger M.O. (2008). The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046-3082.
21. Hedges T. and Scriven A. (2008). Sun safety: what are the health messages? J. R. Soc. Promot. Health 128, 164-169.
22. Hsu C.L. and Yen G.C. (2006). Induction of cell apoptosis in 3T3-L1 preadipocytes by flavonoids is associated with their antioxidant activity. Mol. Nutr. Food Res. 50, 1072-1079.
23. Jackson A., Wilkinson C., Hood K. and Pill R. (2000). Does experience predict knowledge and behavior with respect to cutaneous melanoma, moles, and sun exposure? Possible outcome measures. Behav. Med. 26, 74-79.
24. Janssen O.E. and Hilz H. (1989). Differentiation of 3T3-L1 preadipocytes induced by inhibitors of poly(ADP-ribose) polymerase and by related noninhibitory acids. Eur. J. Biochem. 180, 595-602.
25. Ju B.G., Lunyak V.V., Perissi V., Garcia-Bassets I., Rose D.W., Glass C.K. and Rosenfeld M.G. (2006). A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312, 1798-1802.
26. Kasper B., D'Hondt V., Vereecken P. and Awada A. (2007). Novel treatment strategies for malignant melanoma: a new beginning? Crit. Rev. Oncol. Hematol. 62, 16-22.
27. Kim M.J., Deplewski D., Ciletti N., Michel S., Reichert U. and Rosenfield R.L. (2001). Limited cooperation between peroxisome proliferatoractivated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol. Genet. Metab. 74, 362-369.
28. Lawson D.D., Moore D.H. 2nd, Schneider J.S. and Sagebiel R.W. (1994). Nevus counting as a risk factor for melanoma: comparison of self-count with count by physician. J. Am. Acad. Dermatol. 31, 438-444.
29. Mabley J.G., Horváth E.M., Murthy K.G., Zsengellér Z., Vaslin A., Benko R., Kollai M. and Szabó C. (2005) Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J. Pharmacol. Exp. Ther. 315, 812-820.
30. Malanga M. and Althaus F.R. (1994). Poly(ADP-ribose) molecules formed during DNA repair in vivo. J. Biol. Chem. 269, 17691-17696.
31. Marghoob A.A., Slade J., Kopf A.W., Salopek T.G., Rigel D.S. and Bart R.S. (1996). Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br. J. Dermatol. 135, 704-711.
32. Martin-Oliva D., Aguilar-Quesada R., O'Valle F., Munoz-Gamez J.A., Martinez-Romero R., Garcia Del Moral R., Ruiz de Almodovar J.M., Villuendas R., Piris M.A. and Oliver F.J. (2006). Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 66, 5744-5756.
33. McCullough L.D., Zeng Z., Blizzard K.K., Debchoudhury I. and Hurn P.D. (2005). Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J. Cereb. Blood Flow. Metab. 25, 502-512.
34. Miyamoto T., Kakizawa T. and Hashizume K. (1999). Inhibition of nuclear receptor signalling by poly(ADP-ribose) polymerase. Mol. Cell. Biol. 19, 2644-2649.
35. Obrosova I.G., Minchenko A.G., Frank R.N., Seigel G.M., Zsengeller Z., Pacher P., Stevens M.J. and Szabo C. (2004). Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int. J. Mol. Med. 14, 55-64.
36. Pachernik J., Hampl A., Soucek K., Kovarikova M., Andrysik Z., Hofmanova J. and Kozubik A. (2002). Multiple biological effects of inhibitors of arachidonic acid metabolism on human keratinocytes. Arch. Dermatol. Res. 293, 626-633.
37. Plummer R., Jones C., Middleton M., Wilson R., Evans J., Olsen A., Curtin N., Boddy A., McHugh P., Newell D., Harris A., Johnson P., Steinfeldt H., Dewji R., Wang D., Robson L. and Calvert H. (2008). Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923.
38. Rosenfield R.L., Kentsis A., Deplewski D. and Ciletti N. (1999). Rat preputial sebocyte differentiation involves peroxisome proliferatoractivated receptors. J. Invest. Dermatol. 112, 226-232.
39. Ross R., Gillitzer C., Kleinz R., Schwing J., Kleinert H., Forstermann U. and Reske-Kunz A.B. (1998). Involvement of NO in contact hypersensitivity. Int. Immunol. 10, 61-69.
40. Sander C.S., Hamm F., Elsner P. and Thiele J.J. (2003). Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br. J. Dermatol. 148, 913-922.
41. Sato T., Han F. and Yamamoto A. (2008). The biology and management of uveal melanoma. Curr. Oncol. Rep. 10, 431-438.
42. Schadendorf D. (2002). Is there a standard for the palliative treatment of melanoma? Onkologie 25, 74-76.
43. Schreiber V., Dantzer F., Ame J.C. and de Murcia G. (2006). Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528.
44. Singh A.D., Rennie I.G., Seregard S., Giblin M. and McKenzie J. (2004). Sunlight exposure and pathogenesis of uveal melanoma. Surv. Ophthalmol. 49, 419-428.
45. Staibano S., Pepe S., Lo Muzio L., Somma P., Mascolo M., Argenziano G., Scalvenzi M., Salvatore G., Fabbrocini G., Molea G., Bianco A.R., Carlomagno C. and De Rosa G. (2005). Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol. 36, 724-731.
46. Szabo C., Pacher P., Swanson R.A. (2006) Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. 27, 626-630.
47. Szabo E., Virag L., Bakondi E., Gyure L., Hasko G., Bai P., Hunyadi J., Gergely P. and Szabo C. (2001). Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J. Invest. Dermatol. 117, 74-80.
48. Tentori L., Leonetti C., Scarsella M., D'Amati G., Vergati M., Portarena I., Xu W., Kalish V., Zupi G., Zhang J. and Graziani G. (2003). Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 9, 5370-5379.
49. Tentori L., Leonetti C., Scarsella M., Muzi A., Vergati M., Forini O., Lacal P.M., Ruffini F., Gold B., Li W., Zhang J. and Graziani G. (2005). Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur. J. Cancer 41, 2948-2957.
50. Virag L. and Szabo C. (2002). The therapeutic potential of poly(ADPribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429.
51. Yuan M., Siegel C., Zeng Z., Li J., Liu F. and McCullough L.D. (2009). Sex differences in the response to activation of the poly (ADPribose) polymerase pathway after experimental stroke. Exp Neurol. 217, 210-218.